N1-methylnicotinamide (MNAM) as a guardian of cardiovascular system
| Autor: | Hamid Reza Nejabati, Masoud Pezeshkian, Mohammad Nouri, Ahmadreza Jodati, Naser Safaie, Zeinab Latifi, Aynaz Mihanfar, Mohammad Valiloo, Amir Fattahi |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Niacinamide Physiology Clinical Biochemistry Prostacyclin Coronary Artery Disease 030204 cardiovascular system & hematology Pharmacology Nitric Oxide Cardiovascular System Nitric oxide Coronary artery disease 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Lipid droplet Medicine Humans Nicotinamide business.industry Cell Biology Lipid Droplets medicine.disease Atherosclerosis Epoprostenol Vasoprotective 030104 developmental biology medicine.anatomical_structure chemistry business N1 methylnicotinamide medicine.drug Artery |
| Zdroj: | Journal of cellular physiology. 233(10) |
| ISSN: | 1097-4652 |
| Popis: | Atherosclerosis is identified as the formation of atherosclerotic plaques, which could initiate the formation of a blood clot in which its growth to coronary artery can lead to a heart attack. N-methyltransferase (NNMT) is an enzyme that converts the NAM (nicotinamide) to its methylated form, N1-methylnicotinamide (MNAM). Higher levels of MNAM have been reported in cases with coronary artery disease (CAD). Further, MNAM increases endothelial prostacyclin (PGI2) and nitric oxide (NO) and thereby causes vasorelaxation. The vasoprotective, anti-inflammatory and anti-thrombotic roles of MNAM have been well documented; however, the exact underlying mechanisms remain to be clarified. Due to potential role of MNAM in the formation of lipid droplets (LDs), it might exert its function in coordination with lipids, and their targets. In this study, we summarized the roles of MNAM in cardiovascular system and highlighted its possible mode of actions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text